中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2013年
11期
804-807
,共4页
熊伟%汤钊猷%任正刚%黄修燕%贾庆安%谢晓莹%沈沪佳
熊偉%湯釗猷%任正剛%黃脩燕%賈慶安%謝曉瑩%瀋滬佳
웅위%탕쇠유%임정강%황수연%가경안%사효형%침호가
肝肿瘤,实验性%松友饮%小鼠,裸%药物疗法%肿瘤侵润%肿瘤转移
肝腫瘤,實驗性%鬆友飲%小鼠,裸%藥物療法%腫瘤侵潤%腫瘤轉移
간종류,실험성%송우음%소서,라%약물요법%종류침윤%종류전이
Liver neoplasms,experimental%Songyou Yin%Mice,nude%Drug therapy%Neoplasm invasiveness%Neoplasm metastasis
目的 探讨中药松友饮对化疗后残余肝癌细胞侵袭转移潜能的影响及相关机制.方法 采用人肝癌MHCC97L细胞构建奥沙利铂化疗后的残余肝癌裸鼠原位移植模型.成瘤后,实验组裸鼠以2.1 g/kg、4.2 g/kg和8.4 g/kg的松友饮灌胃,对照组裸鼠灌服生理盐水,检测松友饮对化疗后残余肝癌生长、转移及对裸鼠生存时间的影响.结果 松友饮可有效降低化疗后残余肝癌的肺转移能力,对照组、2.1 g/kg松友饮治疗组、4.2 g/kg松友饮治疗组和8.4 g/kg松友饮治疗组裸鼠的肺转移率分别为86.7%(13/15)、73.3%(11/15)、40.0% (6/15)和20.0%(3/15),与对照组比较,4.2 g/kg松友饮治疗组和8.4g/kg松友饮治疗组裸鼠肺转移率显著下降(P=0.021,P=0.001).松友饮可延长残余肝癌再接种裸鼠的生存时间,对照组、2.1 g/kg松友饮治疗组、4.2 g/kg松友饮治疗组和8.4g/kg松友饮治疗组裸鼠的生存时间分别为(53.83 ±4.71)d、(56.50 ±6.09)d、(66.67 ±5.61)d和(81.17±7.36)d,与对照组比较,4.2 g/kg松友饮治疗组和8.4 g/kg松友饮治疗组裸鼠生存时间延长(P =0.002,P=0.001).松友饮治疗后,残余肝癌组织的上皮-间质转化(EMT)现象显著减少,E-cadherin表达恢复,钙黏蛋白转换现象逆转.结论 松友饮可有效抑制化疗后残余肝癌组织的EMT,降低残余肝癌组织侵袭转移潜能,延长残余肝癌再接种裸鼠的生存时间.松友饮与化疗药物合用有可能进一步提高肝癌化疗的疗效.
目的 探討中藥鬆友飲對化療後殘餘肝癌細胞侵襲轉移潛能的影響及相關機製.方法 採用人肝癌MHCC97L細胞構建奧沙利鉑化療後的殘餘肝癌裸鼠原位移植模型.成瘤後,實驗組裸鼠以2.1 g/kg、4.2 g/kg和8.4 g/kg的鬆友飲灌胃,對照組裸鼠灌服生理鹽水,檢測鬆友飲對化療後殘餘肝癌生長、轉移及對裸鼠生存時間的影響.結果 鬆友飲可有效降低化療後殘餘肝癌的肺轉移能力,對照組、2.1 g/kg鬆友飲治療組、4.2 g/kg鬆友飲治療組和8.4 g/kg鬆友飲治療組裸鼠的肺轉移率分彆為86.7%(13/15)、73.3%(11/15)、40.0% (6/15)和20.0%(3/15),與對照組比較,4.2 g/kg鬆友飲治療組和8.4g/kg鬆友飲治療組裸鼠肺轉移率顯著下降(P=0.021,P=0.001).鬆友飲可延長殘餘肝癌再接種裸鼠的生存時間,對照組、2.1 g/kg鬆友飲治療組、4.2 g/kg鬆友飲治療組和8.4g/kg鬆友飲治療組裸鼠的生存時間分彆為(53.83 ±4.71)d、(56.50 ±6.09)d、(66.67 ±5.61)d和(81.17±7.36)d,與對照組比較,4.2 g/kg鬆友飲治療組和8.4 g/kg鬆友飲治療組裸鼠生存時間延長(P =0.002,P=0.001).鬆友飲治療後,殘餘肝癌組織的上皮-間質轉化(EMT)現象顯著減少,E-cadherin錶達恢複,鈣黏蛋白轉換現象逆轉.結論 鬆友飲可有效抑製化療後殘餘肝癌組織的EMT,降低殘餘肝癌組織侵襲轉移潛能,延長殘餘肝癌再接種裸鼠的生存時間.鬆友飲與化療藥物閤用有可能進一步提高肝癌化療的療效.
목적 탐토중약송우음대화료후잔여간암세포침습전이잠능적영향급상관궤제.방법 채용인간암MHCC97L세포구건오사리박화료후적잔여간암라서원위이식모형.성류후,실험조라서이2.1 g/kg、4.2 g/kg화8.4 g/kg적송우음관위,대조조라서관복생리염수,검측송우음대화료후잔여간암생장、전이급대라서생존시간적영향.결과 송우음가유효강저화료후잔여간암적폐전이능력,대조조、2.1 g/kg송우음치료조、4.2 g/kg송우음치료조화8.4 g/kg송우음치료조라서적폐전이솔분별위86.7%(13/15)、73.3%(11/15)、40.0% (6/15)화20.0%(3/15),여대조조비교,4.2 g/kg송우음치료조화8.4g/kg송우음치료조라서폐전이솔현저하강(P=0.021,P=0.001).송우음가연장잔여간암재접충라서적생존시간,대조조、2.1 g/kg송우음치료조、4.2 g/kg송우음치료조화8.4g/kg송우음치료조라서적생존시간분별위(53.83 ±4.71)d、(56.50 ±6.09)d、(66.67 ±5.61)d화(81.17±7.36)d,여대조조비교,4.2 g/kg송우음치료조화8.4 g/kg송우음치료조라서생존시간연장(P =0.002,P=0.001).송우음치료후,잔여간암조직적상피-간질전화(EMT)현상현저감소,E-cadherin표체회복,개점단백전환현상역전.결론 송우음가유효억제화료후잔여간암조직적EMT,강저잔여간암조직침습전이잠능,연장잔여간암재접충라서적생존시간.송우음여화료약물합용유가능진일보제고간암화료적료효.
Objective To investigate the effects of a Chinese herbal extract Songyou Yin on residual hepatocellular carcinoma after chemotherapy in nude mice and the relevant mechanisms.Methods Orthotopic nude mouse models bearing residual hepatocellular carcinoma after chemotherapy was established using human liver carcinoma MHCC97L cells.Three different doses of Songyon Yin (2.1 g/kg,4.2 g/kg and 8.4 g/kg) were administered to the mice in the trial groups by intragastric gavage,respectively.The mice in the control group were administered physiological saline.The tumor growth,metastasis and survival in the mice of each group were recorded.The corresponding mechanisms were studied.Results The pulmonary metastasis rates of the control group and 2.1g/kg,4.2g/kg,8.4g/kg Songyou Yin treatment group were 86.7%,73.3%,40.0%,and 20.0%,respectively,and the survivals of these groups were 53.83 ± 4.71,56.50 ± 6.09,66.67 ± 5.61,81.17 ± 7.36 days,respectively.Compared with the mice in the control group,mice in the 4.2 g/kg,8.4 g/kg Songyou Yin treatment groups had a lower pulmonary metastasis rate (P =0.021 and P =0.001,respectively) and longer survival (P =0.002 and P =0.001,respectively).A restoration of E-cadherin expression and a concomitant reduction of N-cadherin expression were detected in the tumors of the 4.2 g / kg and 8.4 g / kg Songyou Yin treatment groups.Conclusions Songyou Yin effectively inhibits the invasion and metastasis of the residual hepatocellular carcinoma after chemotherapy in nude mice through attenuating the epithelia-mesenchymal transition and prolongs the survival.Songyon Yin may have potential to promote the efficacy of chemotherapy in hepatocellular carcinoma.